Amitabh Chandra - Faculty & Research - Harvard Business School
Photo of Amitabh Chandra

Amitabh Chandra

Visiting Professor of Business Administration

General Management

Amitabh Chandra is the Malcolm Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. He is a member of the Congressional Budget Office's (CBO) Panel of Health Advisors, and is a Research Associate at the IZA Institute in Bonn, Germany and at the National Bureau of Economic Research (NBER). His research focuses on productivity and cost-growth in healthcare, medical malpractice, and racial disparities in healthcare.

His research has been has been published in the American Economic Review, the Journal of Political Economy, the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs.

Chandra has testified to the United States Senate and the United States Commission on Civil Rights. His research has been featured in the New York Times, the Washington Post, CNN, Newsweek, and on National Public Radio. In 2011 he served as Massachusetts' Special Commissioner on Provider Price Reform. In 2013, he founded Health Engine, a company that reduces the price of healthcare.

Professor Chandra is an elected member of the Institute of Medicine, the first-prize recipient of the Upjohn Institute's Dissertation Award, the Kenneth Arrow Award for best paper in health economics, and the Eugene Garfield Award for the impact of medical research. In 2012, he was awarded American Society of Health Economists (ASHE) medal. The ASHE Medal is awarded biennially to the economist age 40 or under who has made the most significant contributions to the field of health economics.

At HBS, Professor Chandra is teaching in the MD/MBA programs as well as in the Executive Education Programs.

Journal Articles
  1. Innovation Incentives and Biomarkers

    Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra

    Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis and prognosis, predict treatment efficacy or toxicity, serve as markers of disease progression, and serve as auxiliary endpoints for clinical trials. Some have multiple uses, while others have a specialized role, resulting in diverse incentives across players in the healthcare system.

    Keywords: Health Care and Treatment; Innovation and Invention; Research and Development; Markets;

    Citation:

    Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "Innovation Incentives and Biomarkers." Clinical Pharmacology & Therapeutics (forthcoming).  View Details
  2. How Economics Can Shape Precision Medicines

    Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra

    Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated with unproductive therapies while more easily uncovering therapeutic signals. However, such research initiatives alone will not deliver new medicines to patients in the absence of strong incentives to bring new products to market. We examine the unique economics of precision medicines and associated biomarkers, placing an emphasis on the factors affecting their development, pricing, and access.

    Keywords: Health Care and Treatment; Research; Economics; Motivation and Incentives;

    Citation:

    Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.  View Details